Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The university spun out Syndexa Pharmaceuticals Corp. to develop compounds that target molecular
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury